FindTrial
Sign In

Peginterferon

DRUG10 trials

Sponsors

National Institute on Drug Abuse (NIDA), Vertex Pharmaceuticals Incorporated, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, Merck Sharp & Dohme LLC, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions

Chronic Hepatitis CEnd Stage Renal DiseaseHCV InfectionHIV-1 and Hepatitis C Co-InfectionHemophiliaHepatitis B VirusHepatitis CHepatitis C, Chronic

Phase 1

VX-950 and Peginterferon for Hepatitis C
CompletedNCT00251199
Vertex Pharmaceuticals IncorporatedHepatitis C
Start: 2005-10-31End: 2006-03-31Target: 20Updated: 2007-12-21
Viral Kinetics in HCV Clearance in Subjects With Hemophilia
CompletedNCT01704521
Kenneth ShermanChronic Hepatitis C, Hemophilia
Start: 2012-12-31End: 2014-10-31Updated: 2015-04-06

Phase 2

Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance
CompletedNCT00665353
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsHIV-1 and Hepatitis C Co-Infection
Start: 2009-03-31End: 2011-12-31Updated: 2018-10-12
High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1
CompletedNCT00735969
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Chronic Hepatitis C
Start: 2008-08-31End: 2013-06-30Updated: 2014-10-20
Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
CompletedNCT00978497
Hoffmann-La RocheHCV Infection
Start: 2009-09-30End: 2011-08-31Updated: 2017-03-31
This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C
CompletedNCT01528735
Boehringer IngelheimHepatitis C, Chronic
Start: 2012-02-29End: 2013-08-31Updated: 2016-04-13

Phase 3

Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)
CompletedNCT00732641
Merck Sharp & Dohme LLCMultiple Myeloma
Start: 2000-12-31End: 2010-11-30Updated: 2017-04-04

Phase 4

A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)
NCT01731301
Liver Institute of VirginiaChronic Hepatitis C, End Stage Renal Disease
Start: 2013-01-31End: 2015-01-31Target: 20Updated: 2012-11-22

Unknown Phase

Bridging Active Heroin Users to Hepatitis C Treatment Using Buprenorphine - 1
CompletedNCT00249574
National Institute on Drug Abuse (NIDA)Hepatitis C, Heroin Dependence
Start: 2003-06-30End: 2006-06-30Target: 10Updated: 2017-01-16
The Beneficial Effect of Vitamin D Supplement to Peg Interferon Alpha 2a or to Telbivudine Monotherapy in Patients With Chronic Hepatitis B Virus (HBV) Infection
NCT01083251
Ziv HospitalHepatitis B Virus
Start: 2010-03-31End: 2012-12-31Target: 120Updated: 2011-01-19

Related Papers

Open‐label phase 2 study of faldaprevir, deleobuvir and ribavirin in Japanese treatment‐naive patients with chronic hepatitis C virus genotype 1 infection
Hepatology Research2015-05-20